Pramlintide / Metreleptin
One of two clinical-stage programs in obesity, the pramlintide/metreleptin combination reflects the tremendous potential of Amylin’s integrated neurohormonal strategy in developing novel, safe, and effective new therapies for weight loss.
- Pramlintide, the active ingredient in SYMLIN®, is a synthetic analog of amylin, a neurohormone secreted by the pancreas that is known to play a key role in the regulation of appetite, food intake and postprandial glucose concentration.
- Metreleptin is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy homeostasis, fat and glucose metabolism and body weight.
In a proof-of-concept study completed in November 2008, patients treated with a combination of pramlintide and metreleptin reduced body weight on average by 12.7 percent over 24 weeks—representing an average loss of 25 pounds. Weight loss continued through the end of the study, with no evidence of plateau.
Based on these significant results, a Phase 2B pramlintide/metreleptin clinical study is underway.